Skip to main content

Rheumatoid Arthritis

ALN
Results from a recent study show patients with rheumatoid arthritis have an approximately 20% increased risk for heart failure, independent of other risk factors.
Rheumatology Consultant
Steven Romano, MD, executive vice president and chief scientific officer at Mallinckrodt, answers our questions about his team’s research on the effects of Acthar therapy on patients with rheumatoid arthritis.
ALN
Researchers identified two novel inflammatory markers that show promise for assessing disease activity among patients with rheumatoid arthritis.
Rheumatology Consultant
He discusses his research that evaluated whether β-2 glycoprotein 1 IgA antibodies can predict coronary plaque burden and progression, and whether the antibodies moderate the effect of inflammation on atherosclerosis among patients with rheumatoid arthritis.
Rheumatology Consultant
He talks about his study that evaluated whether biologic disease-modifying antirheumatic drugs reduce long-term risk of cardiovascular events in patients with rheumatoid arthritis, as well as their mechanism of action.
Back to Top